Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

December 18, 2025

Conditions

Pancreatic Acinar Cell Carcinoma

Interventions

DRUG

Olaparib

Administered orally (300 mg) twice daily continuously for 28-day cycles for up to 2 years.

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT05286827 - Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | Biotech Hunter | Biotech Hunter